Compare TOL & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TOL | GH |
|---|---|---|
| Founded | 1967 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.7B | 13.3B |
| IPO Year | 1994 | 2018 |
| Metric | TOL | GH |
|---|---|---|
| Price | $146.82 | $90.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 19 |
| Target Price | ★ $164.44 | $119.79 |
| AVG Volume (30 Days) | 1.1M | ★ 2.1M |
| Earning Date | 05-19-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.68% | N/A |
| EPS Growth | N/A | ★ 6.74 |
| EPS | ★ 2.19 | N/A |
| Revenue | ★ $7,143,258,000.00 | $982,021,000.00 |
| Revenue This Year | N/A | $33.30 |
| Revenue Next Year | $6.01 | $28.27 |
| P/E Ratio | $66.95 | ★ N/A |
| Revenue Growth | N/A | ★ 32.88 |
| 52 Week Low | $93.52 | $36.36 |
| 52 Week High | $168.36 | $120.74 |
| Indicator | TOL | GH |
|---|---|---|
| Relative Strength Index (RSI) | 59.52 | 53.42 |
| Support Level | $128.61 | $89.32 |
| Resistance Level | $150.45 | $101.77 |
| Average True Range (ATR) | 3.81 | 5.54 |
| MACD | 1.58 | 0.65 |
| Stochastic Oscillator | 85.13 | 69.78 |
Toll Brothers Inc is the luxury homebuilder in the USA, operating in over 60 markets across 24 states. The Fort Washington, Pennsylvania-headquartered homebuilder caters to affluent first-time, move-up, active-adult, and second-homebuyers. Toll Brothers has shifted in recent years to a greater mix of speculative, or "quick move-in" homes. The homebuilder has also expanded its price points, with a greater emphasis on "affordable luxury. Traditional homebuilding accounts for the majority of Toll Brothers' earnings, but the firm also offers ancillary mortgage, title, insurance, and other services.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.